Kailera Therapeutics Inc KLRA

$VKTX $GPCR $KLRA $LLY $NVO Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs: https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html

$VKTX at these prices, i'm a buyer of $GPCR and $KLRA as well...

$GPCR $KLRA $LLY $NVO $VKTX fidelity MM is less complicated than that. They may be thinking Lilly took the market and no competition long term. And with novo and others repeated trials failure , probably believing only Lilly knows how make molecules. All that wrong.

$VKTX $GPCR $KLRA I have to admit, Fidelity is the top holder in all of these including $NVO and $LLY. Might be spot on here..

$KLRA Cagrisema is GLP/Amylin and these are not interchangeable with GLP/GIP. Amylin dual agonists increase side effects whereas GIP dual agonists decrease side effects. Cagrisema is an inferior drug to Tirzepatide (WL, side effects, A1C)… KLRA chose the correct MOA

$GPCR $VKTX $KLRA I know many of us watch the biotech obesity segment as a whole and it has gotten HAMMERED the past couple months across the board. KLRA's data wasn't great in July/Aug, so that explains their drop. GPCR announced successful SAD testing on the world's first oral amylin and stock has dropped ever since. VKTX had great SQ data, dilution, and crash. Anyway, seems like there is a concerted effort to bring these stocks down. Looking for someone more familiar with market dynamics to shed some light on the recent sector crash. I have two theories: 1. Institutional investors aren't concerned with any of these companies getting BP deals in the next 3-6 months and collectively are shorting them down to make $$$ and then planning to make money on the way back up. "Taking advantage of the ridiculously long Ph3 trials". 2. BP is somehow controlling the institutional investors and are trying to suppress the share price on these companies to prevent commercial scaling funding.

Did you realize that Kailera ( $KLRA ) acquired the commercial rights to the compound at the center of its research from this very same Chinese company (Jiangsu Hengrui Pharmaceuticals)? $NVO also has to think about the future. A 100-year-old company doesn’t think in 1–2–3-year timeframes. If it did, that would be a very serious problem. And besides, as a first-generation dual agonist, there’s always oral CagriSema in the pipeline.